These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16010419)

  • 1. High-throughput tissue microarray analysis of COX2 expression in urinary bladder cancer.
    Wild PJ; Kunz-Schughart LA; Stoehr R; Burger M; Blaszyk H; Simon R; Gasser T; Mihatsch M; Sauter G; Hartmann A
    Int J Oncol; 2005 Aug; 27(2):385-91. PubMed ID: 16010419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the endothelin axis in noninvasive and superficially invasive bladder cancer: relation to clinicopathologic and molecular prognostic parameters.
    Eltze E; Wild PJ; Wülfing C; Zwarthoff EC; Burger M; Stoehr R; Korsching E; Hartmann A
    Eur Urol; 2009 Nov; 56(5):837-45. PubMed ID: 18945538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. P16 immunoreactivity is an independent predictor of tumor progression in minimally invasive urothelial bladder carcinoma.
    Krüger S; Mahnken A; Kausch I; Feller AC
    Eur Urol; 2005 Apr; 47(4):463-7. PubMed ID: 15774242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferative status is a risk index for recurrence in primary superficial (pTa/T1) low-grade urothelial bladder carcinoma.
    Su JS; Arima K; Hasegawa M; Franco OE; Yanagawa M; Sugimura Y; Kawamura J
    Hinyokika Kiyo; 2003 Nov; 49(11):649-58. PubMed ID: 14719452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined analysis of cyclooxygenase-2 expression with p53 and Ki-67 in nonsmall cell lung cancer.
    Tsubochi H; Sato N; Hiyama M; Kaimori M; Endo S; Sohara Y; Imai T
    Ann Thorac Surg; 2006 Oct; 82(4):1198-204. PubMed ID: 16996907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
    Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
    Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
    Mahnken A; Kausch I; Feller AC; Krüger S
    Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer?
    Gudjónsson S; Bendahl PO; Chebil G; Höglund M; Lindgren D; Lundberg LM; Lövgren K; Fernö M; Månsson W; Liedberg F
    Scand J Urol Nephrol; 2011 Sep; 45(4):270-7. PubMed ID: 21504385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.
    Rao J; Seligson D; Visapaa H; Horvath S; Eeva M; Michel K; Pantuck A; Belldegrun A; Palotie A
    Cancer; 2002 Sep; 95(6):1247-57. PubMed ID: 12216092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship of the histologic grade at the deep invasive front and the expression of Ki-67 antigen and p53 protein in oral squamous cell carcinoma.
    Kurokawa H; Zhang M; Matsumoto S; Yamashita Y; Tanaka T; Tomoyose T; Takano H; Funaki K; Fukuyama H; Takahashi T; Sakoda S
    J Oral Pathol Med; 2005 Nov; 34(10):602-7. PubMed ID: 16202080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.
    Fromont G; Rouprêt M; Amira N; Sibony M; Vallancien G; Validire P; Cussenot O
    Eur Urol; 2005 Nov; 48(5):764-70. PubMed ID: 16126329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic significance of neuron-associated protein expression in non-muscle-invasive urothelial bladder cancer.
    Mhawech-Fauceglia P; Ali L; Cheney RT; Groth J; Herrmann FR
    J Clin Pathol; 2009 Aug; 62(8):710-4. PubMed ID: 19638542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGFR3 and p53 protein expressions in patients with pTa and pT1 urothelial bladder cancer.
    Mhawech-Fauceglia P; Cheney RT; Fischer G; Beck A; Herrmann FR
    Eur J Surg Oncol; 2006 Mar; 32(2):231-7. PubMed ID: 16412606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of cyclin D1 and E1 expression with disease progression and biomarkers in patients with nonmuscle-invasive urothelial cell carcinoma of the bladder.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    Urol Oncol; 2007; 25(6):468-75. PubMed ID: 18047954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
    Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
    Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclooxygenase-2 expression on urothelial and inflammatory cells of cystoscopic biopsies and urine cytology as a possible predictive marker for bladder carcinoma.
    Moussa M; Omran Z; Nosseir M; Lotfy A; Swellam T
    APMIS; 2009 Jan; 117(1):45-52. PubMed ID: 19161536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P53 expression in small cell carcinoma of the urinary bladder: biological and prognostic implications.
    Wang X; Jones TD; Maclennan GT; Yang XJ; Lopez-Beltran A; Eble JN; Koch MO; Lin H; Baldridge LA; Tretiakova M; Cheng L
    Anticancer Res; 2005; 25(3B):2001-4. PubMed ID: 16158936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.